
In this Q&A, Malhotra discusses how tirzepatide impacts obstructive sleep apnea treatment.
Atul Malhotra, MD, UC San Diego Health

In this Q&A, Malhotra discusses how tirzepatide impacts obstructive sleep apnea treatment.

FDA approval of tirzepatide for OSA sparks a surge in referrals as experts highlight weight loss benefits, symptom relief, and patient selection.

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.

September 29th 2025